Zacks Investment Research upgraded shares of Dynavax Technologies Corp. (NASDAQ:DVAX) from a sell rating to a hold rating in a research note released on Monday.

According to Zacks, “Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax’s clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. “

Other equities research analysts also recently issued reports about the stock. S&P Equity Research upped their price objective on shares of Dynavax Technologies Corp. from $11.28 to $16.01 in a report on Friday, September 2nd. William Blair reaffirmed a buy rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th. RBC Capital Markets set a $4.00 price objective on shares of Dynavax Technologies Corp. and gave the company a hold rating in a report on Monday, November 14th. Finally, Cowen and Company reaffirmed an outperform rating and set a $45.00 price objective on shares of Dynavax Technologies Corp. in a report on Tuesday, September 6th. Four analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $20.14.

Shares of Dynavax Technologies Corp. (NASDAQ:DVAX) opened at 4.60 on Monday. The company’s 50 day moving average is $8.70 and its 200 day moving average is $13.04. The company’s market capitalization is $177.22 million. Dynavax Technologies Corp. has a one year low of $3.20 and a one year high of $29.86.

Dynavax Technologies Corp. (NASDAQ:DVAX) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.75) by $0.15. The company had revenue of $0.20 million for the quarter, compared to the consensus estimate of $2.44 million. Dynavax Technologies Corp. had a negative net margin of 2,650.25% and a negative return on equity of 78.57%. Dynavax Technologies Corp.’s quarterly revenue was down 83.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.82) EPS. Equities research analysts predict that Dynavax Technologies Corp. will post ($3.21) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Dynavax Technologies Corp. (DVAX) Upgraded to “Hold” at Zacks Investment Research” was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2016/11/29/dynavax-technologies-corp-dvax-upgraded-to-hold-at-zacks-investment-research.html.

A number of large investors have recently made changes to their positions in the stock. State Street Corp increased its stake in shares of Dynavax Technologies Corp. by 49.1% in the first quarter. State Street Corp now owns 1,665,452 shares of the biopharmaceutical company’s stock worth $32,038,000 after buying an additional 548,310 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Dynavax Technologies Corp. by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,521,695 shares of the biopharmaceutical company’s stock worth $22,187,000 after buying an additional 33,834 shares during the last quarter. Senvest Management LLC boosted its position in shares of Dynavax Technologies Corp. by 43.9% in the third quarter. Senvest Management LLC now owns 1,436,016 shares of the biopharmaceutical company’s stock worth $15,064,000 after buying an additional 438,285 shares during the last quarter. BlackRock Fund Advisors boosted its position in shares of Dynavax Technologies Corp. by 6.1% in the third quarter. BlackRock Fund Advisors now owns 1,075,267 shares of the biopharmaceutical company’s stock worth $11,280,000 after buying an additional 62,094 shares during the last quarter. Finally, BlackRock Institutional Trust Company N.A. boosted its position in shares of Dynavax Technologies Corp. by 1.4% in the third quarter. BlackRock Institutional Trust Company N.A. now owns 955,946 shares of the biopharmaceutical company’s stock worth $10,028,000 after buying an additional 13,116 shares during the last quarter. 82.28% of the stock is currently owned by institutional investors and hedge funds.

Dynavax Technologies Corp. Company Profile

Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are focused on vaccines and cancer immunotherapy. The Company’s lead vaccine product candidate is HEPLISAV-B, an investigational adult hepatitis B vaccine, which combines its TLR9 agonist adjuvant and recombinant hepatitis B surface antigen (rHBsAg).

5 Day Chart for NASDAQ:DVAX

Receive News & Stock Ratings for Dynavax Technologies Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corp. and related stocks with our FREE daily email newsletter.